91桃色

Archives of Science
Open 91桃色

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91桃色 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open 91桃色 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Commentary   
  • Arch Sci 8: 237,
  • DOI: 10.4172/science.1000237

Biologics and Biosimilars: Innovations and Challenges in the Pharmaceutical Industry

Ho Ging*
Department of Economics, the Chinese University of Hong Kong, China
*Corresponding Author : Ho Ging, Department of Economics, the Chinese University of Hong Kong, China, Email: ho_ging@gmail.com

Received Date: Sep 02, 2024 / Published Date: Sep 30, 2024

Abstract

Biologics and biosimilars are reshaping the landscape of modern medicine by providing new treatment options for complex diseases such as cancer, autoimmune disorders, and diabetes. Biologics, large and complex molecules derived from living organisms, have revolutionized therapeutic approaches, offering more targeted treatments with improved efficacy and safety profiles. Biosimilars, the near-identical copies of biologics, offer a more affordable alternative, promising to make life-saving treatments accessible to a broader population. This article explores the innovations in biologics and biosimilars, highlighting their roles in the pharmaceutical industry, the regulatory challenges involved in their development, and the ongoing efforts to ensure their safety, efficacy, and affordability. By discussing the current state of biologics and biosimilars, as well as their future potential, the article aims to provide a comprehensive understanding of these groundbreaking therapies and the challenges that remain in their widespread adoption

Citation: Ging H (2024) Biologics and Biosimilars: Innovations and Challenges in the Pharmaceutical Industry. Arch Sci 8: 237 Doi: 10.4172/science.1000237

Copyright: © 2024 Ging H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top